1-(2-methyl-4-imidazolyl)-2-bromoethanone hydrobromide | 82982-52-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(2-methyl-4-imidazolyl)-2-bromoethanone hydrobromide
• 英文别名: 4-Bromoacetyl-2-methylimidazole Hydrobromide；2-bromo-1-(2-methylimidazol-4-yl)ethanone hydrobromide；2-bromo-1-(2-methyl-1H-imidazol-4-yl)-ethanone hydrobromide；2-bromo-1-(2-methyl-1H-imidazol-5-yl)ethanone;hydrobromide
• CAS: 82982-52-3
• 化学式: BrH*C₆H₇BrN₂O
• 分子量: 283.95
• InChiKey: MVTGVDHNHMILAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.87
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  45.8
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(2-methyl-4-imidazolyl)-2-bromoethanone hydrobromide 、 脒基硫脲 生成 2-[4-(2-methyl-1H-imidazol-5-yl)-2,3-dihydro-1,3-thiazol-2-yl]guanidine;hydrobromide
  参考文献：
  名称：

  REITER, L. A.

  摘要：

  DOI：
• 作为产物：
  描述：

  4-乙酰基-2-甲基咪唑 在 溴 作用下， 以 氢溴酸 为溶剂， 以2.8 g (51%)的产率得到1-(2-methyl-4-imidazolyl)-2-bromoethanone hydrobromide
  参考文献：
  名称：

  Process for preparation of 4-acetyl-2-substituted-imidazoles

  摘要：

  该专利描述了一种中间体的化合物，其化学式为##STR1## 其中R.sup.1和R.sup.2分别为（C.sub.1-C.sub.4）烷基或取在一起为（C.sub.2-C.sub.4）烷基，以及它们在制备化合物的过程中的应用，该化合物的化学式为##STR2## 其中R为（C.sub.1-C.sub.6）烷基或（CH.sub.2）.sub.n Ar，Ar为苯基或经Cl，Br，F，CH.sub.3或OCH.sub.3单取代的苯基，n为2至4；包括在反应惰性溶剂和碱的存在下，将其中一种中间体与公式为##STR3## 的胺基嘧啶接触的方法；以及制备进一步中间体1,2-二氯-1-丁烯-3-酮的方法。

  公开号：

  US04482723A1

文献信息

• 2-Guanidino-4-heteroarylthiazoles
  申请人：Pfizer Inc.

  公开号：US04374843A1

  公开（公告）日：1983-02-22

  A series of 2-guanidino-4-heteroarylthiazoles, wherein the heteroaryl substituent is selected from thiazolyl, triazolyl, imidazolyl, and 2-alkyl, 2-amino and 2-carboxamido derivatives thereof, are disclosed. The novel compounds have activity as antisecretory agents and histamine H.sub.2 antagonists and are useful for the treatment of gastric hyperacidity and peptic ulcers. Also disclosed are pharmaceutical compositions containing the novel compounds of this invention and a method of using the compounds in the treatment of gastric hyperacidity and peptic ulcers. Novel intermediates useful in the preparation of the novel antisecretory compounds are also described.

  本发明揭示了一系列2-胍基-4-杂环芳基噻唑，其中杂环芳基取代基选自噻唑基、三唑基、咪唑基以及其2-烷基、2-氨基和2-羧酰胺衍生物。这些新颖的化合物具有抗分泌作用和组胺H.sub.2拮抗剂活性，可用于治疗胃酸过多和消化性溃疡。还揭示了含有本发明新化合物的药物组合物以及使用这些化合物治疗胃酸过多和消化性溃疡的方法。还描述了在制备新型抗分泌化合物中有用的新颖中间体。
• Formulation of antiinflammatory drugs
  申请人：Pfizer Inc.

  公开号：US04636498A1

  公开（公告）日：1987-01-13

  An improved antiinflammatory composition and method of treating inflammation which employs a combination of an antiinflammatory agent (e.g. indomethacin or an oxicam) with a histamine-H.sub.2 antagonist selected from the group consisting of 2-guanidino-4-(4-imidazolyl)thiazole, 2-guanidino-4-(2-methyl-4-imidazolyl )thiazole, 2-(N-benzyl-N'-guanidino)-4-(2-methyl-4-imidazolyl)thiazole, 2-(N-pentyl-N'-guanidino)-4-(2-methyl-4-imidazolyl)thiazole and 2-guanidino-4-[2-(hexylamino)-4-imidazolyl]thiazole.

  一种改进的抗炎组合物及治疗炎症的方法，使用抗炎剂（例如吲哚美辛或氧化康）与组选自2-胍基-4-(4-咪唑基)噻唑、2-胍基-4-(2-甲基-4-咪唑基)噻唑、2-(N-苄基-N'-胍基)-4-(2-甲基-4-咪唑基)噻唑、2-(N-戊基-N'-胍基)-4-(2-甲基-4-咪唑基)噻唑和2-胍基-4-[2-(己基氨基)-4-咪唑基]噻唑的组胺H.sub.2拮抗剂的组合治疗炎症。
• Process for preparation of 4-acetyl-2-substituted-imidazoles
  申请人：Pfizer Inc.

  公开号：US04482723A1

  公开（公告）日：1984-11-13

  Novel intermediates of the formula ##STR1## where R.sup.1 and R.sup.2 are each (C.sub.1 -C.sub.4)alkyl or taken together are (C.sub.2 -C.sub.4)alkylene, and their use in a process for preparation of compounds of the formula ##STR2## where R is (C.sub.1 -C.sub.6)alkyl or (CH.sub.2).sub.n Ar, Ar is phenyl or phenyl monosubstituted by Cl, Br, F, CH.sub.3 or OCH.sub.3 and n is 2 to 4; which comprises contacting one of said intermediates with an amidine of formula ##STR3## in the presence of reaction inert solvent and base; and a process for preparing a further intermediate, 1,2-dichloro-1-buten-3-one.

  该专利描述了一种中间体的化合物，其化学式为##STR1## 其中R.sup.1和R.sup.2分别为（C.sub.1-C.sub.4）烷基或取在一起为（C.sub.2-C.sub.4）烷基，以及它们在制备化合物的过程中的应用，该化合物的化学式为##STR2## 其中R为（C.sub.1-C.sub.6）烷基或（CH.sub.2）.sub.n Ar，Ar为苯基或经Cl，Br，F，CH.sub.3或OCH.sub.3单取代的苯基，n为2至4；包括在反应惰性溶剂和碱的存在下，将其中一种中间体与公式为##STR3## 的胺基嘧啶接触的方法；以及制备进一步中间体1,2-二氯-1-丁烯-3-酮的方法。
• Haloacetyl imidazoles
  申请人：Pfizer Inc.

  公开号：US04452987A1

  公开（公告）日：1984-06-05

  A series of 2-guanidino-4-heteroarylthiazoles, wherein the heteroaryl substituent is selected from thiazolyl, triazolyl, imidazolyl, and 2-alkyl, 2-amino and 2-carboxamido derivatives thereof, are disclosed. The novel compounds have activity as antisecretory agents and histamine H.sub.2 antagonists and are useful for the treatment of gastric hyperacidity and peptic ulcers. Also disclosed are pharmaceutical compositions containing the novel compounds of this invention and a method of using the compounds in the treatment of gastric hyperacidity and peptic ulcers. Novel intermediates useful in the preparation of the novel antisecretory compounds are also described.

  本发明揭示了一系列2-胍基-4-杂环芳基噻唑化合物，其中杂环芳基取代基选择自噻唑基、三唑基、咪唑基和2-烷基、2-氨基和2-羧酰胺衍生物。这些新型化合物具有抗分泌作用和组胺H.sub.2拮抗剂作用，适用于治疗胃酸过多和消化性溃疡。本发明还揭示了含有这些新型化合物的制药组合物以及使用这些化合物治疗胃酸过多和消化性溃疡的方法。还描述了制备新型抗分泌化合物的新型中间体。
• 2-guanidino-4-heteroarylthiazoles
  申请人：Pfizer Inc.

  公开号：US04590299A1

  公开（公告）日：1986-05-20

  A series of 2-guanidino-4-heteroarylthiazoles, wherein the heteroaryl substituent is selected from thiazolyl, triazolyl, imidazolyl, and 2-alkyl, 2-amino and 2-carboxamido derivatives thereof, are disclosed. The novel compounds have activity as antisecretory agents and histamine H.sub.2 antagonists and are useful for the treatment of gastric hyperacidity and peptic ulcers. Also disclosed are pharmaceutical compositions containing the novel compounds of this invention and a method of using the compounds in the treatment of gastric hyperacidity and peptic ulcers. Novel intermediates useful in the preparation of the novel antisecretory compounds are also described.

  本发明揭示了一系列2-胍基-4-杂环芳基噻唑化合物，其中杂环芳基取代基选自噻唑基、三唑基、咪唑基和2-烷基、2-氨基和2-羧酰胺衍生物。这些新型化合物具有抗分泌作用和组胺H.sub.2 拮抗剂活性，可用于治疗胃酸过多和消化性溃疡。本发明还揭示了含有这些新型化合物的制药组合物以及使用这些化合物治疗胃酸过多和消化性溃疡的方法。还描述了制备新型抗分泌化合物的新型中间体。